WO2013040564A2 - Anticorps reconnaissant un épitope conçu arbitrairement d'au moins trois résidus d'acides aminés dans un peptide, et procédé de génération de celui-ci - Google Patents
Anticorps reconnaissant un épitope conçu arbitrairement d'au moins trois résidus d'acides aminés dans un peptide, et procédé de génération de celui-ci Download PDFInfo
- Publication number
- WO2013040564A2 WO2013040564A2 PCT/US2012/055771 US2012055771W WO2013040564A2 WO 2013040564 A2 WO2013040564 A2 WO 2013040564A2 US 2012055771 W US2012055771 W US 2012055771W WO 2013040564 A2 WO2013040564 A2 WO 2013040564A2
- Authority
- WO
- WIPO (PCT)
- Prior art keywords
- amino acid
- acid residues
- peptide
- antibody
- peptide vaccine
- Prior art date
Links
- 108090000765 processed proteins & peptides Proteins 0.000 title claims abstract description 46
- 125000000539 amino acid group Chemical group 0.000 title claims abstract description 35
- 238000000034 method Methods 0.000 title claims description 15
- 229940023041 peptide vaccine Drugs 0.000 claims abstract description 32
- 241000894007 species Species 0.000 claims abstract description 13
- 239000000203 mixture Substances 0.000 claims abstract description 6
- 102000004196 processed proteins & peptides Human genes 0.000 claims description 21
- 230000027455 binding Effects 0.000 claims description 18
- 238000004519 manufacturing process Methods 0.000 claims description 7
- 230000009385 viral infection Effects 0.000 claims description 6
- 241000282414 Homo sapiens Species 0.000 claims description 5
- 208000036142 Viral infection Diseases 0.000 claims description 5
- 230000001419 dependent effect Effects 0.000 claims description 3
- 150000001413 amino acids Chemical class 0.000 abstract description 19
- 241000713772 Human immunodeficiency virus 1 Species 0.000 abstract description 12
- 238000013461 design Methods 0.000 abstract description 12
- 238000000338 in vitro Methods 0.000 abstract description 2
- 210000002966 serum Anatomy 0.000 description 19
- 241000283973 Oryctolagus cuniculus Species 0.000 description 18
- 230000003053 immunization Effects 0.000 description 18
- 238000002649 immunization Methods 0.000 description 18
- 230000003472 neutralizing effect Effects 0.000 description 18
- 241000700605 Viruses Species 0.000 description 17
- 230000002163 immunogen Effects 0.000 description 15
- 235000001014 amino acid Nutrition 0.000 description 12
- 230000005875 antibody response Effects 0.000 description 11
- 238000006386 neutralization reaction Methods 0.000 description 10
- 108090000623 proteins and genes Proteins 0.000 description 10
- 241000725303 Human immunodeficiency virus Species 0.000 description 9
- 239000000427 antigen Substances 0.000 description 9
- 102000036639 antigens Human genes 0.000 description 9
- 108091007433 antigens Proteins 0.000 description 9
- 238000012512 characterization method Methods 0.000 description 9
- 241001465754 Metazoa Species 0.000 description 8
- 230000000694 effects Effects 0.000 description 8
- 241001529936 Murinae Species 0.000 description 7
- 235000018102 proteins Nutrition 0.000 description 7
- 102000004169 proteins and genes Human genes 0.000 description 7
- 229960005486 vaccine Drugs 0.000 description 7
- 101710120037 Toxin CcdB Proteins 0.000 description 6
- 230000008901 benefit Effects 0.000 description 6
- 210000004027 cell Anatomy 0.000 description 6
- 230000006698 induction Effects 0.000 description 6
- 241000711549 Hepacivirus C Species 0.000 description 5
- 241000699666 Mus <mouse, genus> Species 0.000 description 5
- 241000699670 Mus sp. Species 0.000 description 5
- 210000004408 hybridoma Anatomy 0.000 description 5
- 208000015181 infectious disease Diseases 0.000 description 5
- DHMQDGOQFOQNFH-UHFFFAOYSA-N Glycine Chemical compound NCC(O)=O DHMQDGOQFOQNFH-UHFFFAOYSA-N 0.000 description 4
- 108010067902 Peptide Library Proteins 0.000 description 4
- 102100036011 T-cell surface glycoprotein CD4 Human genes 0.000 description 4
- 101800001690 Transmembrane protein gp41 Proteins 0.000 description 4
- 238000010790 dilution Methods 0.000 description 4
- 239000012895 dilution Substances 0.000 description 4
- 238000012360 testing method Methods 0.000 description 4
- 230000003612 virological effect Effects 0.000 description 4
- LGGRPYXPOUIMKG-OJICBBQQSA-N (2S)-2-[[(2S)-2-[[(2S,3S)-2-[[(2S,3R)-2-[[2-[[(2S,3S)-2-[[(2S,3S)-2-[[(2S)-4-amino-2-[[(2S)-6-amino-2-[[(2S,3R)-2-[[(2S,3R)-2-[[(2S)-2-[[(2S)-2-[[(2S)-2-[[(2S)-2-[[2-[[(2S)-1-[2-[[(2S,3S)-2-[[(2S)-2-[[(2S,3S)-2-[[(2S)-2-[[(2S)-6-amino-2-[[(2S)-2-[[(2S)-6-amino-2-[[(2S)-4-amino-2-[[(2S)-2-[[(2S)-4-amino-2-[[(2S)-1-[(2S)-2-[[(2S,3R)-2-amino-3-hydroxybutanoyl]amino]-5-(diaminomethylideneamino)pentanoyl]pyrrolidine-2-carbonyl]amino]-4-oxobutanoyl]amino]-3-(4-hydroxyphenyl)propanoyl]amino]-4-oxobutanoyl]amino]hexanoyl]amino]-5-(diaminomethylideneamino)pentanoyl]amino]hexanoyl]amino]-5-(diaminomethylideneamino)pentanoyl]amino]-3-methylpentanoyl]amino]-3-(1H-imidazol-4-yl)propanoyl]amino]-3-methylpentanoyl]amino]acetyl]pyrrolidine-2-carbonyl]amino]acetyl]amino]-5-(diaminomethylideneamino)pentanoyl]amino]propanoyl]amino]-3-phenylpropanoyl]amino]-3-(4-hydroxyphenyl)propanoyl]amino]-3-hydroxybutanoyl]amino]-3-hydroxybutanoyl]amino]hexanoyl]amino]-4-oxobutanoyl]amino]-3-methylpentanoyl]amino]-3-methylpentanoyl]amino]acetyl]amino]-3-hydroxybutanoyl]amino]-3-methylpentanoyl]amino]-5-(diaminomethylideneamino)pentanoyl]amino]-N-[(2S)-1-[[(2S)-1-amino-3-(1H-imidazol-4-yl)-1-oxopropan-2-yl]amino]-1-oxopropan-2-yl]pentanediamide Chemical compound CC[C@H](C)[C@@H](C(=O)N[C@@H](CC1=CNC=N1)C(=O)N[C@@H]([C@@H](C)CC)C(=O)NCC(=O)N2CCC[C@H]2C(=O)NCC(=O)N[C@@H](CCCN=C(N)N)C(=O)N[C@@H](C)C(=O)N[C@@H](CC3=CC=CC=C3)C(=O)N[C@@H](CC4=CC=C(C=C4)O)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CC(=O)N)C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H]([C@@H](C)CC)C(=O)NCC(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H](CCCN=C(N)N)C(=O)N[C@@H](CCC(=O)N)C(=O)N[C@@H](C)C(=O)N[C@@H](CC5=CNC=N5)C(=O)N)NC(=O)[C@H](CCCN=C(N)N)NC(=O)[C@H](CCCCN)NC(=O)[C@H](CCCN=C(N)N)NC(=O)[C@H](CCCCN)NC(=O)[C@H](CC(=O)N)NC(=O)[C@H](CC6=CC=C(C=C6)O)NC(=O)[C@H](CC(=O)N)NC(=O)[C@@H]7CCCN7C(=O)[C@H](CCCN=C(N)N)NC(=O)[C@H]([C@@H](C)O)N LGGRPYXPOUIMKG-OJICBBQQSA-N 0.000 description 3
- 206010003445 Ascites Diseases 0.000 description 3
- 238000002965 ELISA Methods 0.000 description 3
- 241000726047 Infectious flacherie virus Species 0.000 description 3
- 239000005089 Luciferase Substances 0.000 description 3
- 241001112090 Pseudovirus Species 0.000 description 3
- 238000001514 detection method Methods 0.000 description 3
- 230000005764 inhibitory process Effects 0.000 description 3
- 230000003993 interaction Effects 0.000 description 3
- 230000001404 mediated effect Effects 0.000 description 3
- 102000005962 receptors Human genes 0.000 description 3
- 108020003175 receptors Proteins 0.000 description 3
- 230000001225 therapeutic effect Effects 0.000 description 3
- 239000011534 wash buffer Substances 0.000 description 3
- 108091003079 Bovine Serum Albumin Proteins 0.000 description 2
- 102100031650 C-X-C chemokine receptor type 4 Human genes 0.000 description 2
- 241000283707 Capra Species 0.000 description 2
- 238000012286 ELISA Assay Methods 0.000 description 2
- 239000004471 Glycine Substances 0.000 description 2
- 208000031886 HIV Infections Diseases 0.000 description 2
- 101000922348 Homo sapiens C-X-C chemokine receptor type 4 Proteins 0.000 description 2
- 241000430519 Human rhinovirus sp. Species 0.000 description 2
- CKLJMWTZIZZHCS-REOHCLBHSA-N L-aspartic acid Chemical compound OC(=O)[C@@H](N)CC(O)=O CKLJMWTZIZZHCS-REOHCLBHSA-N 0.000 description 2
- 108060001084 Luciferase Proteins 0.000 description 2
- 239000002671 adjuvant Substances 0.000 description 2
- 238000001042 affinity chromatography Methods 0.000 description 2
- 235000003704 aspartic acid Nutrition 0.000 description 2
- 230000002238 attenuated effect Effects 0.000 description 2
- OQFSQFPPLPISGP-UHFFFAOYSA-N beta-carboxyaspartic acid Natural products OC(=O)C(N)C(C(O)=O)C(O)=O OQFSQFPPLPISGP-UHFFFAOYSA-N 0.000 description 2
- 229940098773 bovine serum albumin Drugs 0.000 description 2
- 108091036078 conserved sequence Proteins 0.000 description 2
- 238000010276 construction Methods 0.000 description 2
- 230000028993 immune response Effects 0.000 description 2
- 210000000987 immune system Anatomy 0.000 description 2
- 230000001965 increasing effect Effects 0.000 description 2
- 230000001939 inductive effect Effects 0.000 description 2
- 244000005700 microbiome Species 0.000 description 2
- 230000035772 mutation Effects 0.000 description 2
- 239000013612 plasmid Substances 0.000 description 2
- 230000009257 reactivity Effects 0.000 description 2
- 230000035945 sensitivity Effects 0.000 description 2
- 238000006467 substitution reaction Methods 0.000 description 2
- 230000008685 targeting Effects 0.000 description 2
- 241000712461 unidentified influenza virus Species 0.000 description 2
- 238000005406 washing Methods 0.000 description 2
- DQJCDTNMLBYVAY-ZXXIYAEKSA-N (2S,5R,10R,13R)-16-{[(2R,3S,4R,5R)-3-{[(2S,3R,4R,5S,6R)-3-acetamido-4,5-dihydroxy-6-(hydroxymethyl)oxan-2-yl]oxy}-5-(ethylamino)-6-hydroxy-2-(hydroxymethyl)oxan-4-yl]oxy}-5-(4-aminobutyl)-10-carbamoyl-2,13-dimethyl-4,7,12,15-tetraoxo-3,6,11,14-tetraazaheptadecan-1-oic acid Chemical compound NCCCC[C@H](C(=O)N[C@@H](C)C(O)=O)NC(=O)CC[C@H](C(N)=O)NC(=O)[C@@H](C)NC(=O)C(C)O[C@@H]1[C@@H](NCC)C(O)O[C@H](CO)[C@H]1O[C@H]1[C@H](NC(C)=O)[C@@H](O)[C@H](O)[C@@H](CO)O1 DQJCDTNMLBYVAY-ZXXIYAEKSA-N 0.000 description 1
- 208000030507 AIDS Diseases 0.000 description 1
- 241001128034 Amphotropic murine leukemia virus Species 0.000 description 1
- 102100035875 C-C chemokine receptor type 5 Human genes 0.000 description 1
- 101710149870 C-C chemokine receptor type 5 Proteins 0.000 description 1
- 102000014914 Carrier Proteins Human genes 0.000 description 1
- 108010078791 Carrier Proteins Proteins 0.000 description 1
- 102100027723 Endogenous retrovirus group K member 6 Rec protein Human genes 0.000 description 1
- 108010032976 Enfuvirtide Proteins 0.000 description 1
- 101710121417 Envelope glycoprotein Proteins 0.000 description 1
- 101100279830 Friend murine leukemia virus env gene Proteins 0.000 description 1
- 108010015899 Glycopeptides Proteins 0.000 description 1
- 102000002068 Glycopeptides Human genes 0.000 description 1
- 108090000288 Glycoproteins Proteins 0.000 description 1
- 102000003886 Glycoproteins Human genes 0.000 description 1
- 208000037357 HIV infectious disease Diseases 0.000 description 1
- ONIBWKKTOPOVIA-BYPYZUCNSA-N L-Proline Chemical compound OC(=O)[C@@H]1CCCN1 ONIBWKKTOPOVIA-BYPYZUCNSA-N 0.000 description 1
- QNAYBMKLOCPYGJ-REOHCLBHSA-N L-alanine Chemical compound C[C@H](N)C(O)=O QNAYBMKLOCPYGJ-REOHCLBHSA-N 0.000 description 1
- ROHFNLRQFUQHCH-YFKPBYRVSA-N L-leucine Chemical compound CC(C)C[C@H](N)C(O)=O ROHFNLRQFUQHCH-YFKPBYRVSA-N 0.000 description 1
- OUYCCCASQSFEME-QMMMGPOBSA-N L-tyrosine Chemical compound OC(=O)[C@@H](N)CC1=CC=C(O)C=C1 OUYCCCASQSFEME-QMMMGPOBSA-N 0.000 description 1
- 102000007330 LDL Lipoproteins Human genes 0.000 description 1
- ROHFNLRQFUQHCH-UHFFFAOYSA-N Leucine Natural products CC(C)CC(N)C(O)=O ROHFNLRQFUQHCH-UHFFFAOYSA-N 0.000 description 1
- KDXKERNSBIXSRK-UHFFFAOYSA-N Lysine Natural products NCCCCC(N)C(O)=O KDXKERNSBIXSRK-UHFFFAOYSA-N 0.000 description 1
- 239000004472 Lysine Substances 0.000 description 1
- 241000124008 Mammalia Species 0.000 description 1
- 206010035226 Plasma cell myeloma Diseases 0.000 description 1
- 229920001213 Polysorbate 20 Polymers 0.000 description 1
- ONIBWKKTOPOVIA-UHFFFAOYSA-N Proline Natural products OC(=O)C1CCCN1 ONIBWKKTOPOVIA-UHFFFAOYSA-N 0.000 description 1
- 210000001744 T-lymphocyte Anatomy 0.000 description 1
- 235000004279 alanine Nutrition 0.000 description 1
- 230000000890 antigenic effect Effects 0.000 description 1
- 238000003556 assay Methods 0.000 description 1
- 210000003719 b-lymphocyte Anatomy 0.000 description 1
- 230000015572 biosynthetic process Effects 0.000 description 1
- 210000004369 blood Anatomy 0.000 description 1
- 239000008280 blood Substances 0.000 description 1
- 239000007853 buffer solution Substances 0.000 description 1
- 239000003153 chemical reaction reagent Substances 0.000 description 1
- 238000010367 cloning Methods 0.000 description 1
- 238000012761 co-transfection Methods 0.000 description 1
- 230000021615 conjugation Effects 0.000 description 1
- 238000007796 conventional method Methods 0.000 description 1
- XUJNEKJLAYXESH-UHFFFAOYSA-N cysteine Natural products SCC(N)C(O)=O XUJNEKJLAYXESH-UHFFFAOYSA-N 0.000 description 1
- 238000004925 denaturation Methods 0.000 description 1
- 230000036425 denaturation Effects 0.000 description 1
- 230000001627 detrimental effect Effects 0.000 description 1
- 231100000673 dose–response relationship Toxicity 0.000 description 1
- 239000003814 drug Substances 0.000 description 1
- 238000005516 engineering process Methods 0.000 description 1
- 230000002708 enhancing effect Effects 0.000 description 1
- 239000013604 expression vector Substances 0.000 description 1
- 235000013861 fat-free Nutrition 0.000 description 1
- 239000012634 fragment Substances 0.000 description 1
- 238000010230 functional analysis Methods 0.000 description 1
- 208000033519 human immunodeficiency virus infectious disease Diseases 0.000 description 1
- 230000001900 immune effect Effects 0.000 description 1
- 230000036039 immunity Effects 0.000 description 1
- 230000005847 immunogenicity Effects 0.000 description 1
- 230000002401 inhibitory effect Effects 0.000 description 1
- 102000006495 integrins Human genes 0.000 description 1
- 108010044426 integrins Proteins 0.000 description 1
- 108010045069 keyhole-limpet hemocyanin Proteins 0.000 description 1
- 238000013507 mapping Methods 0.000 description 1
- 239000012528 membrane Substances 0.000 description 1
- 235000013336 milk Nutrition 0.000 description 1
- 239000008267 milk Substances 0.000 description 1
- 210000004080 milk Anatomy 0.000 description 1
- 201000000050 myeloid neoplasm Diseases 0.000 description 1
- 239000013642 negative control Substances 0.000 description 1
- 239000002773 nucleotide Substances 0.000 description 1
- 239000002245 particle Substances 0.000 description 1
- 210000003819 peripheral blood mononuclear cell Anatomy 0.000 description 1
- 230000002093 peripheral effect Effects 0.000 description 1
- 235000010486 polyoxyethylene sorbitan monolaurate Nutrition 0.000 description 1
- 239000000256 polyoxyethylene sorbitan monolaurate Substances 0.000 description 1
- 229920001184 polypeptide Polymers 0.000 description 1
- 229920000915 polyvinyl chloride Polymers 0.000 description 1
- 239000004800 polyvinyl chloride Substances 0.000 description 1
- 230000003389 potentiating effect Effects 0.000 description 1
- 230000001566 pro-viral effect Effects 0.000 description 1
- 238000000746 purification Methods 0.000 description 1
- 230000009467 reduction Effects 0.000 description 1
- 230000003362 replicative effect Effects 0.000 description 1
- 238000011160 research Methods 0.000 description 1
- 238000003757 reverse transcription PCR Methods 0.000 description 1
- 238000012163 sequencing technique Methods 0.000 description 1
- 230000000405 serological effect Effects 0.000 description 1
- 210000004989 spleen cell Anatomy 0.000 description 1
- 230000019635 sulfation Effects 0.000 description 1
- 238000005670 sulfation reaction Methods 0.000 description 1
- 238000003786 synthesis reaction Methods 0.000 description 1
- 230000002194 synthesizing effect Effects 0.000 description 1
- 238000002560 therapeutic procedure Methods 0.000 description 1
- 238000001890 transfection Methods 0.000 description 1
- 230000007704 transition Effects 0.000 description 1
- 230000010415 tropism Effects 0.000 description 1
- OUYCCCASQSFEME-UHFFFAOYSA-N tyrosine Natural products OC(=O)C(N)CC1=CC=C(O)C=C1 OUYCCCASQSFEME-UHFFFAOYSA-N 0.000 description 1
- 238000011144 upstream manufacturing Methods 0.000 description 1
- 238000002255 vaccination Methods 0.000 description 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/08—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from viruses
- C07K16/10—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from viruses from RNA viruses
- C07K16/1036—Retroviridae, e.g. leukemia viruses
- C07K16/1045—Lentiviridae, e.g. HIV, FIV, SIV
- C07K16/1063—Lentiviridae, e.g. HIV, FIV, SIV env, e.g. gp41, gp110/120, gp160, V3, PND, CD4 binding site
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/14—Antivirals for RNA viruses
- A61P31/18—Antivirals for RNA viruses for HIV
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/04—Immunostimulants
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
- C07K2317/34—Identification of a linear epitope shorter than 20 amino acid residues or of a conformational epitope defined by amino acid residues
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Immunology (AREA)
- Organic Chemistry (AREA)
- Virology (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Animal Behavior & Ethology (AREA)
- Oncology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Molecular Biology (AREA)
- Communicable Diseases (AREA)
- AIDS & HIV (AREA)
- Genetics & Genomics (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Hematology (AREA)
- Engineering & Computer Science (AREA)
- Biochemistry (AREA)
- Biophysics (AREA)
- Tropical Medicine & Parasitology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Peptides Or Proteins (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Preparation Of Compounds By Using Micro-Organisms (AREA)
Abstract
L'invention concerne un vaccin peptidique qui est un mélange de différentes espèces peptidiques, chaque espèce ayant un nombre de résidus d'acides aminés fixes et un nombre de résidus aléatoires. Les résidus fixes sont les mêmes résidus d'acides aminés aux positions correspondantes dans chaque espèce du mélange, alors que les résidus aléatoires sont aléatoirement tout acide aminé candidat disponible choisi à dessein. Le degré de randomisation peut être également choisi selon la conception dans une situation particulière. Ce type de vaccin peptidique s'est avéré être apte à induire des anticorps extrêmement spécifiques, dirigés contre des épitopes qui sont autrement difficiles pour induire des anticorps in vitro, par exemple le triplet GPG dans le V3 de glp20 de VIH-1.
Priority Applications (7)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP2014530928A JP2014527085A (ja) | 2011-09-17 | 2012-09-17 | ペプチドにおける３個以上のアミノ酸残基の任意に設計されたエピトープを認識する抗体およびその生成方法 |
| EP12832007.4A EP2755687A4 (fr) | 2011-09-17 | 2012-09-17 | Anticorps reconnaissant un épitope conçu arbitrairement d'au moins trois résidus d'acides aminés dans un peptide, et procédé de génération de celui-ci |
| AU2012308212A AU2012308212A1 (en) | 2011-09-17 | 2012-09-17 | Antibody recognizing arbitrarily designed epitope of three or more amino acid residues in a peptide and method of generating thereof |
| HK15101049.2A HK1200359A1 (en) | 2011-09-17 | 2012-09-17 | Antibody recognizing arbitrarily designed epitope of three or more amino acid residues in a peptide and method of generating thereof |
| CA2855781A CA2855781A1 (fr) | 2011-09-17 | 2012-09-17 | Anticorps reconnaissant un epitope concu arbitrairement d'au moins trois residus d'acides amines dans un peptide, et procede de generation de celui-ci |
| CN201280045106.2A CN104039350B (zh) | 2011-09-17 | 2012-09-17 | 任意三个或以上氨基酸残基构成的多肽表位及其相关抗体的诱导 |
| AU2017251715A AU2017251715A1 (en) | 2011-09-17 | 2017-10-24 | Antibody recognizing arbitrarily designed epitope of three or more amino acid residues in a peptide and method of generating thereof |
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201161535988P | 2011-09-17 | 2011-09-17 | |
| US61/535,988 | 2011-09-17 |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| WO2013040564A2 true WO2013040564A2 (fr) | 2013-03-21 |
| WO2013040564A3 WO2013040564A3 (fr) | 2013-06-27 |
Family
ID=47884023
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| PCT/US2012/055771 WO2013040564A2 (fr) | 2011-09-17 | 2012-09-17 | Anticorps reconnaissant un épitope conçu arbitrairement d'au moins trois résidus d'acides aminés dans un peptide, et procédé de génération de celui-ci |
Country Status (7)
| Country | Link |
|---|---|
| EP (1) | EP2755687A4 (fr) |
| JP (2) | JP2014527085A (fr) |
| CN (1) | CN104039350B (fr) |
| AU (2) | AU2012308212A1 (fr) |
| CA (1) | CA2855781A1 (fr) |
| HK (1) | HK1200359A1 (fr) |
| WO (1) | WO2013040564A2 (fr) |
Cited By (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2016062294A1 (fr) * | 2014-10-24 | 2016-04-28 | Versitech Limited | Composés à motif d'adn et procédés pour induire des anticorps spécifiques et une immunité cellulaire |
Families Citing this family (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN111153996B (zh) * | 2020-01-10 | 2021-12-14 | 苏州睿瀛生物技术有限公司 | G蛋白偶联受体的抗体及其制备方法和g蛋白偶联受体试剂盒 |
Family Cites Families (7)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO1995011701A1 (fr) * | 1993-10-26 | 1995-05-04 | Syntello, Inc. | Inhibition de l'infection des muqueuses par le vih |
| CA2175579A1 (fr) * | 1993-10-26 | 1995-05-04 | Chang Yi Wang | Bibliotheques structurees d'antigenes de synthese utilisables a des fins de diagnostic, de vaccin et de therapie |
| US6441140B1 (en) * | 1998-09-04 | 2002-08-27 | Cell Signaling Technology, Inc. | Production of motif-specific and context-independent antibodies using peptide libraries as antigens |
| US9289487B2 (en) * | 1999-09-14 | 2016-03-22 | Antigen Express, Inc. | II-key/antigenic epitope hybrid peptide vaccines |
| FR2809402A1 (fr) * | 2000-05-26 | 2001-11-30 | Dev Des Antigenes Combinatoire | Bibliotheques peptidiques combinatoires convergentes et leur application a la vaccination contre le virus de l'hepatite c |
| EP1725099A4 (fr) * | 2004-02-02 | 2009-08-19 | Mixture Sciences Inc | Melanges de peptides a activite immunomodulatrice |
| CA2701948A1 (fr) * | 2007-10-09 | 2009-04-16 | Technologie Integrale Ltd. | Vaccin preventif contre vih a base d'anticorps specifique de vih |
-
2012
- 2012-09-17 AU AU2012308212A patent/AU2012308212A1/en not_active Abandoned
- 2012-09-17 JP JP2014530928A patent/JP2014527085A/ja active Pending
- 2012-09-17 EP EP12832007.4A patent/EP2755687A4/fr not_active Withdrawn
- 2012-09-17 HK HK15101049.2A patent/HK1200359A1/xx unknown
- 2012-09-17 WO PCT/US2012/055771 patent/WO2013040564A2/fr active Application Filing
- 2012-09-17 CA CA2855781A patent/CA2855781A1/fr not_active Abandoned
- 2012-09-17 CN CN201280045106.2A patent/CN104039350B/zh not_active Expired - Fee Related
-
2017
- 2017-04-18 JP JP2017082368A patent/JP2017141291A/ja active Pending
- 2017-10-24 AU AU2017251715A patent/AU2017251715A1/en not_active Abandoned
Non-Patent Citations (2)
| Title |
|---|
| CHALES-NINO ET AL., VACCINE, vol. 29, 2011, pages 5313 - 5321 |
| KELLER ET AL., VIROLOGY, vol. 193, 1993, pages 709 - 716 |
Cited By (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2016062294A1 (fr) * | 2014-10-24 | 2016-04-28 | Versitech Limited | Composés à motif d'adn et procédés pour induire des anticorps spécifiques et une immunité cellulaire |
| CN107208110A (zh) * | 2014-10-24 | 2017-09-26 | 港大科桥有限公司 | 用于诱导特异性抗体和细胞免疫的dna基序化合物和方法 |
| EP3209784A4 (fr) * | 2014-10-24 | 2018-06-27 | Versitech Limited | Composés à motif d'adn et procédés pour induire des anticorps spécifiques et une immunité cellulaire |
| US10245313B2 (en) | 2014-10-24 | 2019-04-02 | Versitech Limited | DNA motif compounds and methods for inducing specific antibodies and cellular immunity |
Also Published As
| Publication number | Publication date |
|---|---|
| JP2014527085A (ja) | 2014-10-09 |
| WO2013040564A3 (fr) | 2013-06-27 |
| HK1200359A1 (en) | 2015-08-07 |
| EP2755687A2 (fr) | 2014-07-23 |
| AU2017251715A1 (en) | 2017-11-09 |
| EP2755687A4 (fr) | 2015-04-08 |
| AU2012308212A1 (en) | 2014-03-27 |
| CN104039350B (zh) | 2019-07-05 |
| JP2017141291A (ja) | 2017-08-17 |
| CA2855781A1 (fr) | 2013-03-21 |
| CN104039350A (zh) | 2014-09-10 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CA2858347C (fr) | Immunogenes v1v2 | |
| Selvarajah et al. | Comparing antigenicity and immunogenicity of engineered gp120 | |
| Liu et al. | The development of HIV vaccines targeting gp41 membrane-proximal external region (MPER): challenges and prospects | |
| EP0570357A2 (fr) | Peptides induisant des anticorps, qui neutralisent des isolées d'HIV-1 qui divergent génétiquement | |
| Qin et al. | Eliciting neutralizing antibodies with gp120 outer domain constructs based on M-group consensus sequence | |
| Choudhry et al. | Cross-reactive HIV-1 neutralizing monoclonal antibodies selected by screening of an immune human phage library against an envelope glycoprotein (gp140) isolated from a patient (R2) with broadly HIV-1 neutralizing antibodies | |
| Pinter | Roles of HIV-1 Env variable regions in viral neutralization and vaccine development | |
| Zhang et al. | Cross-reactive HIV-1-neutralizing activity of serum IgG from a rabbit immunized with gp41 fused to IgG1 Fc: possible role of the prolonged half-life of the immunogen | |
| Haynes et al. | Analysis of HIV-1 subtype B third variable region peptide motifs for induction of neutralizing antibodies against HIV-1 primary isolates | |
| Kumar et al. | CD4-binding site directed cross-neutralizing scFv monoclonals from HIV-1 subtype C infected Indian children | |
| JPH05503851A (ja) | 中和および／またはａｄｃｃ仲介モノクローナルｈｉｖ抗体 | |
| Visciano et al. | In vivo alteration of humoral responses to HIV-1 envelope glycoprotein gp120 by antibodies to the CD4-binding site of gp120 | |
| AU2017251715A1 (en) | Antibody recognizing arbitrarily designed epitope of three or more amino acid residues in a peptide and method of generating thereof | |
| Humbert et al. | Inducing cross-clade neutralizing antibodies against HIV-1 by immunofocusing | |
| US20040241641A1 (en) | Peptides mimicking a cryptic epitope of gp41 hiv-1 | |
| Gao et al. | Cross-reactive monoclonal antibodies to multiple HIV-1 subtype and SIVcpz envelope glycoproteins | |
| Cham et al. | Neutralization and infectivity characteristics of envelope glycoproteins from human immunodeficiency virus type 1 infected donors whose sera exhibit broadly cross-reactive neutralizing activity | |
| JPH0570493A (ja) | ヒト免疫不全ウイルス（ｈｉｖ）関連免疫調製物 | |
| Ringel et al. | Optimization of the EC26-2A4 epitope in the gp41 membrane proximal external region targeted by neutralizing antibodies from an elite controller | |
| US10660951B2 (en) | Antibody recognizing arbitrarily designed epitope of three or more amino acid residues in a peptide and method of generating thereof | |
| AU2005223352B2 (en) | Novel Tat complexes, and vaccines comprising them | |
| S Shcherbakova et al. | Artificial polyepitope HIV-1 immunogen containing mimotope of 2F5 epitope | |
| Steimer et al. | HIV-1 neutralization directed to epitopes other than linear V3 determinants | |
| Ching et al. | Alterations in the immunogenic properties of soluble trimeric human immunodeficiency virus type 1 envelope proteins induced by deletion or heterologous substitutions of the V1 loop | |
| JP2013528370A (ja) | Ｈｉｖ−１サブタイプｃエンベロープ糖タンパク質における遺伝子シグネチャー |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| 121 | Ep: the epo has been informed by wipo that ep was designated in this application |
Ref document number: 12832007 Country of ref document: EP Kind code of ref document: A2 |
|
| ENP | Entry into the national phase |
Ref document number: 2014530928 Country of ref document: JP Kind code of ref document: A |
|
| ENP | Entry into the national phase |
Ref document number: 2855781 Country of ref document: CA |
|
| ENP | Entry into the national phase |
Ref document number: 2012308212 Country of ref document: AU Date of ref document: 20120917 Kind code of ref document: A |
|
| WWE | Wipo information: entry into national phase |
Ref document number: 2012832007 Country of ref document: EP |